M&A / Deals Repligen builds in cell therapy with $1.5bn BioLife takeover PharmaphorumRepligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.Read full story pharminent July 22, 2026 (Last updated: July 22, 2026) Pharmaphorum Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028Next: Trump Threatens 100%–200% Tariffs on Imported Generic Drugs Related Stories M&A / Deals Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics pharminent July 20, 2026 M&A / Deals Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover pharminent July 16, 2026 M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot pharminent July 14, 2026
